Granulomatous Enteritis

Granulomatous enteritis is a chronic inflammatory bowel disease (IBD) of the small intestine characterized by the infiltration of the intestinal mucosa and submucosa with macrophages, epithelioid cells, and multinucleated giant cells, forming discrete granulomas. This condition is a subtype of IBD in dogs and cats, distinct from lymphocytic-plasmacytic enteritis, and is often associated with specific infectious agents or idiopathic inflammatory responses. The granulomatous inflammation leads to thickening of the intestinal wall, malabsorption, protein-losing enteropathy, and chronic diarrhea. The disease can be focal, multifocal, or diffuse, and may involve the duodenum, jejunum, and ileum. Systemic manifestations may occur due to chronic inflammation and nutrient malabsorption.

The etiology of granulomatous enteritis is multifactorial. In dogs, the most recognized infectious cause is Mycobacterium avium subspecies paratuberculosis (Johne's disease), though rare. Other mycobacterial species, including Mycobacterium tuberculosis and atypical mycobacteria, can cause granulomatous enteritis. Fungal agents such as Histoplasma capsulatum, Aspergillus spp., and Pythium insidiosum can also induce granulomatous inflammation. In cats, feline infectious peritonitis (FIP) caused by a coronavirus can produce granulomatous lesions in the intestine. Additionally, idiopathic granulomatous enteritis is considered an immune-mediated disorder, possibly triggered by dietary antigens or dysbiosis, leading to a Th1-dominant inflammatory response. Genetic predisposition may play a role, as certain breeds (e.g., Boxers, French Bulldogs) are overrepresented. Environmental factors, including stress and concurrent infections, may precipitate or exacerbate the condition.

Granulomatous enteritis is uncommon in dogs and cats, representing a small percentage of IBD cases. In dogs, it is more frequently reported in young to middle-aged animals, with a median age of 3-5 years. Certain breeds, including Boxers, French Bulldogs, and Weimaraners, appear to have a higher prevalence, suggesting a genetic component. In cats, granulomatous enteritis is often associated with FIP, which is more common in multi-cat environments and shelters. No clear sex predilection is reported. Geographic distribution varies with infectious etiologies: histoplasmosis is endemic in the Mississippi River Valley, while pythiosis is more common in tropical and subtropical regions. Idiopathic cases are seen worldwide. The incidence is low, but the condition is clinically significant due to its chronicity and potential for severe morbidity.

The pathophysiology of granulomatous enteritis involves a dysregulated immune response to either infectious agents or luminal antigens. In infectious cases, the organism invades the intestinal mucosa, where it is phagocytosed by macrophages. Inability of macrophages to kill the organism leads to persistent antigenic stimulation, resulting in the recruitment of T-helper 1 (Th1) cells and the release of pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). This cytokine milieu promotes macrophage activation, epithelioid cell formation, and fusion into multinucleated giant cells, forming granulomas. The granulomas cause architectural distortion of the intestinal villi, leading to malabsorption and increased mucosal permeability. Chronic inflammation also disrupts lymphatic drainage, contributing to protein-losing enteropathy (PLE) and lymphangiectasia. In idiopathic cases, a breakdown in oral tolerance to dietary or microbial antigens is hypothesized, with genetic susceptibility and dysbiosis playing roles. The resulting inflammation is typically transmural, leading to fibrosis and stricture formation over time.

Predisposing factors for granulomatous enteritis include genetic susceptibility, as seen in Boxers and French Bulldogs, which may have defects in innate immunity or regulatory T-cell function. Young age (under 5 years) is a risk factor. Infectious agents are more likely in immunocompromised animals or those with concurrent diseases. Environmental factors such as poor sanitation, overcrowding, and stress can increase exposure to infectious agents. Dietary factors, including food allergies or intolerances, may trigger or exacerbate idiopathic cases. Concurrent immunosuppressive therapy (e.g., corticosteroids) may increase susceptibility to mycobacterial or fungal infections. In cats, FIP is more common in young cats from shelters or catteries, and stress is a known trigger for disease development.

Clinical signs of granulomatous enteritis are often chronic and progressive. The most common signs include chronic diarrhea (small bowel diarrhea, which is often voluminous and may be watery or semi-formed), weight loss, and poor body condition. Vomiting may occur, especially if the stomach or proximal duodenum is involved. In cases of PLE, signs include peripheral edema, ascites, and pleural effusion due to hypoalbuminemia. Abdominal pain may be present, particularly with mesenteric lymphadenopathy or strictures. In infectious cases, systemic signs such as fever, lethargy, and anorexia are more prominent. In cats with FIP, additional signs include ocular and neurological manifestations. Physical examination may reveal thickened intestinal loops, mesenteric lymphadenopathy, and a poor hair coat. In advanced cases, cachexia and muscle wasting are evident.

Differential diagnoses for granulomatous enteritis include: 1) Lymphocytic-plasmacytic enteritis (LPE) - the most common form of IBD, characterized by lymphocytic and plasmacytic infiltration without granulomas; differentiation requires histopathology. 2) Eosinophilic enteritis - infiltration with eosinophils, often associated with parasites or food allergy; peripheral eosinophilia may be present. 3) Intestinal lymphoma - especially in cats, can mimic IBD; requires full-thickness biopsy and immunophenotyping. 4) Histoplasmosis - systemic fungal infection with granulomatous lesions; cytology or histopathology with fungal stains (GMS, PAS) is diagnostic. 5) Pythiosis - granulomatous lesions with eosinophilic infiltration; serology and PCR for Pythium insidiosum. 6) Mycobacterial infection - acid-fast staining of biopsies. 7) Feline infectious peritonitis (FIP) - granulomatous lesions with vasculitis; immunohistochemistry for coronavirus antigen. 8) Intestinal adenocarcinoma - neoplastic mass with obstructive signs; biopsy differentiates. 9) Protein-losing enteropathy due to lymphangiectasia - dilated lymphatics on histopathology. 10) Chronic intussusception or foreign body - imaging and exploratory surgery differentiate.

The diagnostic algorithm for granulomatous enteritis begins with a thorough history and physical examination. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, urinalysis, and fecal examination (including culture and PCR for infectious agents). Serum concentrations of cobalamin and folate are measured to assess small intestinal function. If PLE is suspected, serum albumin and globulin levels, and possibly fecal alpha-1-proteinase inhibitor, are evaluated. Abdominal imaging, including radiography and ultrasonography, is performed to assess intestinal wall thickness, lymphadenopathy, and other abnormalities. Endoscopy with mucosal biopsy is the next step; however, because granulomas may be patchy, full-thickness surgical biopsy is often recommended for definitive diagnosis. Histopathology with special stains (Ziehl-Neelsen for acid-fast bacilli, GMS for fungi) is essential. PCR and culture of biopsy tissue for infectious agents are performed. In cases where FIP is suspected, coronavirus serology and immunohistochemistry on biopsies are indicated. Advanced imaging such as CT or MRI may be used to evaluate for strictures or masses.

Laboratory findings in granulomatous enteritis are nonspecific but supportive. CBC may reveal mild anemia (chronic disease), leukocytosis with monocytosis, and occasionally eosinophilia if parasitic or fungal etiology. Serum biochemistry often shows hypoalbuminemia due to PLE, and hypoglobulinemia or hyperglobulinemia depending on the cause. Liver enzymes may be mildly elevated. Electrolyte imbalances, particularly hypokalemia and hyponatremia, can occur due to diarrhea. Cobalamin (vitamin B12) deficiency is common due to ileal disease, while folate may be low if proximal small intestine is affected. In infectious cases, hyperglobulinemia may be present. Urinalysis is usually unremarkable. Fecal examination may reveal ova or organisms. Specific biomarkers: fecal alpha-1-proteinase inhibitor is elevated in PLE; serum cobalamin and folate are useful. In cats, coronavirus antibody titers may be elevated but are not diagnostic. PCR for mycobacteria, Histoplasma, or Pythium on blood or tissue can be performed.

Radiography: Abdominal radiographs may show a generalized loss of serosal detail due to effusion, or thickened intestinal loops. In cases of PLE, there may be evidence of ascites. Ultrasonography: This is the most valuable imaging modality. Findings include thickening of the intestinal wall (often >5 mm in dogs), loss of normal layering, and hyperechoic mucosal striations. Mesenteric lymphadenopathy is common. In PLE, there may be hyperechoic speckling of the mucosa due to lymphangiectasia. Doppler ultrasound can assess blood flow. Computed Tomography (CT): CT provides detailed cross-sectional images and can identify strictures, masses, and lymphadenopathy. It is particularly useful for surgical planning. Magnetic Resonance Imaging (MRI): MRI is less commonly used but can provide excellent soft tissue contrast. Endoscopy: Endoscopy allows direct visualization of the mucosa, which may appear erythematous, friable, or nodular. Biopsies can be taken, but full-thickness biopsies are preferred for granulomatous disease. Fluoroscopy: Barium contrast studies may show mucosal irregularities or strictures, but are less sensitive than ultrasound.

Cytology: Fine-needle aspiration of thickened intestinal wall or enlarged lymph nodes may reveal macrophages, epithelioid cells, and multinucleated giant cells. In infectious cases, organisms may be seen with appropriate stains (e.g., acid-fast for mycobacteria, GMS for fungi). However, cytology is often inconclusive and histopathology is required. Histopathology: Full-thickness biopsy is the gold standard. Microscopic findings include granulomatous inflammation with aggregates of epithelioid macrophages, multinucleated giant cells, and lymphocytes. The granulomas may be well-formed or poorly organized. There is often transmural inflammation, with fibrosis and lymphatic dilation. Special stains: Ziehl-Neelsen for acid-fast bacilli, Gomori methenamine silver (GMS) and Periodic acid-Schiff (PAS) for fungi. Immunohistochemistry may be used to identify specific infectious agents (e.g., coronavirus in FIP). In idiopathic cases, no infectious agent is identified.

Treatment of granulomatous enteritis depends on the underlying cause. For infectious etiologies, specific antimicrobial therapy is required. For mycobacterial infections, combination therapy with multiple drugs (e.g., clarithromycin, rifampicin, and a fluoroquinolone) is recommended, but treatment is prolonged and prognosis is guarded. For fungal infections, antifungal agents such as itraconazole (5-10 mg/kg PO q24h) or amphotericin B are used. For pythiosis, surgical resection is the treatment of choice, with adjunctive antifungal therapy. For FIP, treatment is primarily supportive, with newer antiviral drugs (e.g., GS-441524) showing promise. For idiopathic granulomatous enteritis, immunosuppressive therapy is the mainstay. Prednisone or prednisolone is initiated at immunosuppressive doses (2 mg/kg/day PO for dogs, 2-4 mg/kg/day for cats), tapered over weeks to months. If response is inadequate, additional immunosuppressants such as cyclosporine (5 mg/kg PO q24h), azathioprine (2 mg/kg PO q24h for dogs), or chlorambucil (0.1-0.2 mg/kg PO q24h for cats) may be added. Dietary management with a highly digestible, low-residue, or hypoallergenic diet is essential. In cases of PLE, a low-fat diet and supplementation with medium-chain triglycerides (MCT) are recommended. Supportive care includes fluid therapy, electrolyte replacement, and nutritional support. In severe cases with strictures or masses, surgical resection may be necessary.

The prognosis for granulomatous enteritis is variable and depends on the underlying cause. For idiopathic cases, the prognosis is fair to good with appropriate immunosuppressive therapy, but long-term management is often required. Many dogs and cats achieve remission, but relapses are common. For infectious causes, the prognosis is guarded to poor, especially for mycobacterial infections and FIP. Mycobacterial infections are difficult to treat and often fatal. Fungal infections have a guarded prognosis, with response to therapy being variable. Pythiosis has a poor prognosis unless complete surgical resection is possible. FIP is almost always fatal, though newer antiviral treatments may improve outcomes. Negative prognostic indicators include severe hypoalbuminemia (<1.5 g/dL), presence of ascites or pleural effusion, and lack of response to initial therapy. Early diagnosis and aggressive treatment improve the chances of a favorable outcome.

Follow-up for granulomatous enteritis involves regular re-evaluations to monitor response to therapy and adjust medications. Initially, re-check appointments should be scheduled every 2-4 weeks. At each visit, a physical examination, body weight, and serum biochemistry (including albumin, globulins, and electrolytes) should be performed. Fecal examinations may be repeated. In cases of PLE, serum albumin should be monitored until normalized. For patients on immunosuppressive therapy, CBC and serum biochemistry should be monitored every 2-4 weeks initially, then every 3-6 months. Drug levels may be monitored for cyclosporine. Repeat abdominal ultrasound may be performed every 3-6 months to assess intestinal wall thickness and lymphadenopathy. Dietary management should be continued long-term. Owners should be educated on signs of relapse, such as recurrence of diarrhea, weight loss, or vomiting, and advised to seek veterinary care promptly. In infectious cases, follow-up may include repeat PCR or cultures to confirm clearance.

Pearls: 1) Always consider infectious causes in young animals with granulomatous enteritis, especially if there is fever or systemic signs. 2) Full-thickness biopsy is essential for diagnosis; endoscopic biopsies may miss granulomas. 3) In PLE, measure fecal alpha-1-proteinase inhibitor to confirm protein loss. 4) Cobalamin supplementation is often necessary; administer at 250-500 μg SC once weekly for 6 weeks, then monthly. 5) Use a stepwise approach to immunosuppressive therapy, starting with corticosteroids and adding other drugs if needed. Pitfalls: 1) Do not delay biopsy in chronic diarrhea cases; early diagnosis improves outcome. 2) Avoid using corticosteroids before obtaining a definitive diagnosis, as they may mask infectious causes. 3) Do not overlook the possibility of intestinal lymphoma, which can mimic IBD; immunophenotyping is crucial. 4) In cats, FIP should be ruled out before starting immunosuppressive therapy. 5) Monitor for drug side effects, especially bone marrow suppression with azathioprine and chlorambucil.

Drug protocols based on Plumb's Veterinary Drug Handbook: 1) Prednisone/Prednisolone: Dogs: 1-2 mg/kg PO q12h for 2-4 weeks, then taper by 25% every 2-4 weeks to lowest effective dose. Cats: 2-4 mg/kg PO q24h, taper similarly. 2) Cyclosporine (modified): Dogs: 5 mg/kg PO q24h; Cats: 5-7 mg/kg PO q24h. Monitor trough levels (target 400-600 ng/mL). 3) Azathioprine: Dogs: 2 mg/kg PO q24h for 2-4 weeks, then q48h. Cats: 0.3 mg/kg PO q48h (use with caution). 4) Chlorambucil: Cats: 0.1-0.2 mg/kg PO q24h or q48h. 5) Metronidazole: 10-15 mg/kg PO q12h for 2-4 weeks (may be used as adjunctive therapy for its immunomodulatory effects). 6) Itraconazole: 5-10 mg/kg PO q24h for fungal infections. 7) Amphotericin B: 0.5-1 mg/kg IV three times weekly, up to a cumulative dose of 8-12 mg/kg. 8) Clarithromycin: 7.5-10 mg/kg PO q12h for mycobacterial infections. 9) Rifampicin: 5-10 mg/kg PO q24h. 10) For FIP, GS-441524: 4-6 mg/kg SC q24h for 12 weeks (investigational). Always adjust dosages for renal or hepatic impairment and monitor for adverse effects.

Evidence-based literature on granulomatous enteritis is limited due to its rarity. Key studies include: 1) A retrospective study by Craven et al. (2004) described clinical features and outcomes in dogs with granulomatous colitis, a related condition, highlighting the importance of histopathology. 2) A study by Simpson et al. (2006) identified adherent and invasive Escherichia coli in granulomatous colitis of Boxers, suggesting a bacterial trigger. 3) In cats, a study by Pedersen (2009) reviewed FIP pathogenesis and treatment, noting the granulomatous lesions. 4) A consensus statement by the ACVIM (2010) on canine chronic enteropathies recommended a diagnostic algorithm including histopathology and treatment trials. 5) A recent study by Sykes et al. (2020) evaluated the use of molecular diagnostics for infectious causes of granulomatous enteritis. 6) The WSAVA Gastrointestinal Standardization Group (2010) provided guidelines for histopathological evaluation of intestinal biopsies. Overall, the literature emphasizes the need for a thorough diagnostic workup and the importance of differentiating infectious from idiopathic causes.